Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Canada to invest up to C$214 mln for research into domestic-made vaccines - PM Trudeau

10/23/2020 | 12:17pm EST

OTTAWA, Oct 23 (Reuters) - Canada will invest up to C$214 million ($162.8 million) to help develop a domestically made COVID-19 vaccine as a second surge of infections across the country worsens, Prime Minister Justin Trudeau said on Friday.

Canada has secured up to 76 million doses of Quebec City-based Medicago's potential virus-like particle vaccine, Trudeau said. It is the first domestically developed vaccine candidate the government has reserved.

The announcement came a day after the country recorded 2,788 new cases in a 24-hour period.

"Yesterday Canada had the highest ever number of new cases of COVID-19. We have to get these numbers down - this is serious and everybody must do their part," Trudeau said in a news conference.

Last month Canada agreed to buy up to 20 million doses of the vaccine candidate produced by AstraZeneca and Oxford University. That is one of several deals Ottawa has signed to secure around 300 million potential shots.

Canada has agreements with Pfizer, Sanofi, GlaxoSmithKline, Moderna, Novavax and Johnson & Johnson for their vaccine candidates.

On Friday, the government also said it would invest up to C$18.2 million in Vancouver-based biotechnology company Precision NanoSystems Inc (PNI) to support a project for pre-clinical and clinical trials for a vaccine. ($1 = 1.3142 Canadian dollars) (Reporting by Steve Scherer and David Ljunggren Editing by Chizu Nomiyama and Jonathan Oatis)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.28% 7770 Delayed Quote.2.14%
EURO / CANADIAN DOLLAR (EUR/CAD) 0.01% 1.55405 Delayed Quote.6.55%
GLAXOSMITHKLINE PLC -0.46% 1383.6 Delayed Quote.-22.23%
MODERNA, INC. 16.35% 127.03 Delayed Quote.549.44%
NOVAVAX, INC. 22.50% 125.69 Delayed Quote.2,477.89%
PFIZER INC. 1.92% 37.23 Delayed Quote.0.30%
SANOFI -0.19% 85.21 Real-time Quote.-4.92%
All news about ASTRAZENECA PLC
11:22aSerum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
11:18aSerum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
10:59aUK regulator set to approve COVID-19 vaccine next week - FT
RE
10:31aIndia's Modi visits key vaccine facilities as COVID-19 cases surge
RE
08:22aUK appoints vaccines minister to oversee COVID inoculations
AQ
08:05aIndia's Modi visits key vaccine facilities as COVID-19 case load surges
RE
03:32aOil prices post weekly gain ahead of OPEC+ meeting
RE
11/27SALESFORCE, DELTA AIR LINES, BEST BU : Stocks That Defined the Week
DJ
11/27Stocks at record high but yields fall, dollar under pressure
RE
11/27Oil prices post weekly gain ahead of OPEC+ meeting
RE
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 43,5x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,49 $
Last Close Price 103,45 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC2.14%135 908
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440